The Peptide Medicines That Are FDA-Approved

When a clinic says "peptides are FDA-approved", it is saying something true and something misleading in the same breath. Dozens of peptide medicines have been through FDA review and are ordinary parts of modern medicine. Most of the peptides sold for recovery, fat loss and anti-aging are not among them. This guide lists the approved ones, what each is approved for, and how to check any product yourself.

Knowing which peptides are approved is the single fastest way to cut through peptide marketing. It tells you whether a product has been tested in randomized trials for the use you are being offered, whether there is an FDA-reviewed label with dosing, contraindications and warnings, and whether manufacturing is held to FDA standards. It also tells you when a clinic is borrowing credibility from one molecule to sell another. If you are weighing any of these medicines, our peptide therapy consultations start from that distinction.

First, what counts as a peptide medicine?

A peptide is a chain of amino acids. Proteins are longer chains. For regulatory purposes FDA draws the line at 40 amino acids: a chain of 40 or fewer is treated as a peptide and regulated as a drug, while a longer chain is treated as a protein and regulated as a biological product.

That definition had a practical consequence in March 2020, when a group of products previously approved as drugs were transitioned to being regulated as biologics. Insulin, whose two chains total 51 amino acids, was one of them. Human growth hormone, at 191 amino acids, was another.

In everyday language, people still call insulin a peptide hormone, and this guide includes it because it is the clearest example of a peptide-family medicine everyone has heard of. Just be aware that when a label or database says "biologic", that is a regulatory category, not a sign that something is fundamentally different or less established.

What "FDA-approved" actually guarantees

Approval means a sponsor submitted evidence from clinical trials and manufacturing data, and FDA concluded that the benefits outweigh the known risks for a specific use. In practical terms, an approved peptide medicine comes with:

• An indication: the condition and population it was shown to help.
• Labeling: dose, route, contraindications, warnings, interactions and known side effects.
• Manufacturing oversight: the product is made to FDA quality standards and facilities are inspected.
• Ongoing safety monitoring: adverse event reporting, and label updates or restrictions when new risks emerge.

What approval does not guarantee is that a medicine is right for you, that it works for uses outside its label, or that a product with a similar name shares its approval.

The approved peptide medicines, by what they treat

This is not an exhaustive list of every approved product, but it covers the peptide medicines patients most often ask about or encounter. Brand names are given for recognition. Indications are summarized; each product's current label has the precise wording.

Diabetes and blood sugar

Chronic weight management and related conditions

These are the approved peptides most people meet, and they are also the most copied. We compare the two leading options in semaglutide vs tirzepatide and cover the full picture in our GLP-1 weight loss guide. Other peptide options for weight are examined in peptides for weight loss beyond GLP-1s.

Bone health

Hormone-sensitive cancers, pituitary and reproductive conditions

Growth hormone axis

Tesamorelin (Egrifta) is a growth-hormone-releasing hormone analogue. FDA approved it in 2010, and its current label indicates it for reducing excess abdominal fat in adults with HIV who have lipodystrophy. The label explicitly says it is not indicated for weight loss management. It is the approved relative of the unapproved secretagogues that wellness clinics sell. We cover it in tesamorelin: the approved GHRH analogue and its limits.

Sermorelin has a history worth getting right. It was approved under the brand name Geref, for diagnosing and treating growth hormone deficiency in children. The manufacturer discontinued the products in 2008, and in a 2013 Federal Register notice FDA determined they were not withdrawn for reasons of safety or effectiveness. We are not aware of any FDA-approved sermorelin product currently on the US market; sermorelin offered by clinics today is typically a compounded preparation. See sermorelin: how it differs from growth hormone.

Somatropin (human growth hormone) is approved for defined conditions such as growth hormone deficiency, but as a 191-amino-acid protein it is regulated as a biologic rather than a peptide drug, and federal law restricts its distribution for unapproved uses. We explain the difference in peptides vs HGH vs SARMs vs steroids.

Sexual health

Bremelanotide (Vyleesi) was approved in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder that causes marked distress and is not due to another medical or psychiatric condition, relationship problems or medication effects. Its label states it is not indicated for postmenopausal women, for men, or to enhance sexual performance, and it is contraindicated in uncontrolled hypertension or known cardiovascular disease. More in PT-141: what it is approved for and what it isn't.

Gut disorders

Skin, rare disease and other specialties

• Afamelanotide (Scenesse), approved in October 2019 as an implant for adults with erythropoietic protoporphyria, a rare disorder causing painful reactions to light. It is not a tanning product; see why melanotan II worries dermatologists.
• Icatibant (Firazyr and generics) for acute attacks of hereditary angioedema.
• Enfuvirtide (Fuzeon) for HIV-1 infection in treatment-experienced patients.
• Eptifibatide and bivalirudin, used in hospitals to prevent clotting during certain heart procedures.
• Ziconotide (Prialt), delivered into the spinal fluid for severe chronic pain.

What is not on the list

None of the following is FDA-approved for any use:

• BPC-157
• TB-500 (a synthetic peptide related to thymosin beta-4)
• CJC-1295 and ipamorelin
• MOTS-c, KPV, Semax, Selank and Epitalon
• AOD-9604
• GHK-Cu as an injectable (copper peptides are common in cosmetics, which are regulated differently)
• Melanotan II

Several of these were the subject of a July 2026 vote by FDA's Pharmacy Compounding Advisory Committee, which narrowly recommended adding BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon to the list of bulk substances that 503A pharmacies may compound from. That vote is non-binding, FDA's own reviewers had concluded none of the seven substances reviewed met the criteria, and any change requires formal rulemaking. It also has nothing to do with approval: a substance on the compounding list is still not an FDA-approved drug. We explain the vote in full in the July 2026 FDA peptide vote, explained. Rules change, so verify the current position with FDA.

Why some peptides get approved and most do not

It is tempting to assume that the unapproved peptides are simply waiting their turn, or that they are being kept off the market for commercial reasons. The reality is more mundane, and more useful to understand.

Approval is expensive and slow. Taking a molecule from animal studies through phased human trials and an FDA application takes years and large sums of money. Companies make that investment when they can protect the result with patents and sell it for a defined condition. Many wellness peptides are old, unpatentable sequences, so nobody has an incentive to fund the trials that would settle whether they work.

Promising animal results often fail in people. Most compounds that look good in rodents never show a clear benefit in human trials, for reasons ranging from different biology to doses that cannot be tolerated. Ipamorelin, for instance, was tested by its developer in patients recovering from bowel surgery and development stopped after disappointing results. That attrition is normal. It is exactly why "works in rats" is not a treatment claim.

Peptides are hard to deliver. Most are broken down in the gut and cleared quickly from the blood. Approved peptide drugs usually involve careful engineering, such as chemical modifications that extend how long they last, or special formulations like the absorption enhancer that makes oral semaglutide possible. A raw peptide from a research vial has none of that development behind it.

Approval needs a defined condition. FDA approves medicines to diagnose, treat or prevent specific diseases. "Recovery", "optimization" and "anti-aging" are not indications a trial can easily be designed around, which is one reason products marketed that way tend to stay in the unapproved space.

None of this means every unapproved peptide is useless. It means the question has not been answered, and marketing that treats it as answered is getting ahead of the evidence.

Compounded versions of approved peptides

A compounded medicine is prepared by a licensed pharmacy for an individual patient or, in the case of outsourcing facilities, in larger batches under stricter oversight. Compounding has a legitimate role, for example when a patient needs a formulation that is not commercially available.

But compounded products are not FDA-approved, even when they contain the same active ingredient as an approved drug. FDA does not review them for safety, effectiveness or quality before they are sold. That gap became very visible during the GLP-1 shortages, when compounded semaglutide and tirzepatide were widely sold; FDA has since warned about dosing errors with compounded GLP-1 products and about versions made with different salt forms of the active ingredient, which are not the same as the approved drug. The rules on compounding copies of approved drugs also tighten once a shortage ends. We cover this in compounded GLP-1s: what to know.

How to check a product yourself in five minutes

1. Get the exact name. Ask for the brand name and the active ingredient. "Semaglutide" is not enough; "Wegovy" or "Ozempic" is checkable.
2. Search Drugs@FDA. FDA's Drugs@FDA database lists approved drug products, approval history and labels. For products regulated as biologics, such as insulin, FDA's Purple Book is the equivalent.
3. Read the label on DailyMed. The NIH DailyMed site has current prescribing information. Read the Indications and Usage section first, then Contraindications and Warnings.
4. Compare the indication to your situation. If your use is not listed, it is off-label. That can be appropriate, but it should be discussed openly.
5. Ask whether you will receive the approved product or a compounded preparation, and which pharmacy fills it.

Off-label prescribing: legitimate, with conditions

Once a drug is approved, licensed clinicians may prescribe it for other uses when they judge it medically appropriate. Off-label prescribing is lawful and common, and in some areas it reflects strong evidence that simply never went through a new approval.

For peptides, the useful questions are the same ones you would ask about any off-label use. What evidence supports it for someone like me? What does the label warn about that still applies? Will insurance cover it (often not)? And is there an approved alternative with better evidence for my goal? A good clinician will answer those directly, and will tell you when the honest answer is that the evidence is thin.

Athletes: approved does not mean permitted

FDA approval and anti-doping rules are separate systems. Some approved peptides are prohibited in sport. Tesamorelin, for example, falls under the World Anti-Doping Agency's S2 category covering growth hormone releasing factors, and other approved hormone-related peptides can also be restricted. If you are tested, check USADA's resources or your sport's governing body, and apply for a Therapeutic Use Exemption before using a prohibited medicine you genuinely need.

Where this leaves you

If your interest in peptides started with an approved medicine, such as a GLP-1 for weight or a bone-building drug your doctor mentioned, you are in well-mapped territory, with labels, trial data and clear monitoring. If it started with a product on the "not approved" list, the question to ask is not only "does it work?" but "what exactly would I be getting, under what authority, and what does the human evidence actually show?"

Either way, a licensed clinician can help you work out which approved options fit your goals and history, what off-label or compounded options exist and their limits, and when the best plan involves no peptide at all. You can book a consultation to go through it. It will not come with a guaranteed prescription, because an honest answer sometimes means saying no.

Common questions

Which peptides are FDA-approved?

Approved peptide medicines include insulin, semaglutide, tirzepatide, liraglutide, exenatide, tesamorelin, bremelanotide, teriparatide, abaloparatide, setmelanotide, leuprolide, octreotide, oxytocin, linaclotide and others, each for specific indications. Popular wellness peptides such as BPC-157 and TB-500 are not approved.

Is BPC-157 FDA-approved?

No. BPC-157 has no FDA approval for any use. A July 2026 advisory committee vote concerned whether pharmacies may compound it, not approval, and the vote was non-binding. See BPC-157 in 2026.

Is compounded semaglutide FDA-approved?

No. Compounded semaglutide contains the same named active ingredient as Ozempic and Wegovy, or sometimes a salt form, but compounded products are not reviewed or approved by FDA.

Is sermorelin FDA-approved?

Sermorelin was previously approved as Geref, which its manufacturer discontinued in 2008. FDA later determined it was not withdrawn for safety or effectiveness reasons. Sermorelin offered today is typically compounded, and compounded preparations are not FDA-approved.

How can I tell if a peptide I've been offered is approved?

Ask for the brand name, then look it up on Drugs@FDA or DailyMed. If there is no brand name, no FDA label and no approved indication, it is not an FDA-approved product.